Verve Therapeutics
215 First Street, Suite 440
Cambridge
MA
02142
United States
Tel: (617) 603-0070
Website: https://www.vervetx.com/
33 articles about Verve Therapeutics
-
Verve Therapeutics is pausing enrollment in the Phase Ib Heart-1 study for its gene editor VERVE-101 after a patient developed grade 3 laboratory abnormalities, the company announced Tuesday.
-
Separate challenges exist for companies developing gene therapies for rare and common cardiovascular conditions, experts told BioSpace.
-
As Vertex and CRISPR Therapeutics’ exa-cel and Verve Therapeutics’ VERVE-101 move forward, questions remain about possible drawbacks of such therapies.
-
After Verve Therapeutics recently announced gene editing therapy results, the company is offering up its stock to the public and Eli Lilly. However, the stock was down 13% Wednesday on the news.
-
When given at potentially therapeutic doses, Verve’s base editor led to strong reductions in LDL cholesterol and PCSK9 levels in patients with heterozygous familial hypercholesterolemia.
-
As Vertex and CRISPR Therapeutics await the monumental potential approval of exa-cel, bluebird bio, Iovance and Rocket Pharmaceuticals wait patiently in the wings.
-
The regulator lifted a clinical hold on Verve Therapeutics’ CRISPR-based therapy clearing its Investigational New Drug application and plans to evaluate VERVE-101 in a Phase I heterozygous familial hypercholesterolemia trial.
-
Eli Lilly has secured the rights to Verve Therapeutics’ gene editing approach, a “one-and-done” method that the companies hope will lower the cardiovascular risk factor lipoprotein(a).
-
Monday, Verve Therapeutics revealed that the FDA has officially requested several buckets of additional safety information to lift the hold on its lead candidate, VERVE-101.
-
Verve Therapeutics’ base editing program has been forced into a detour after the FDA placed a hold on its investigational new drug application. Beam has also posted its own regulatory update.
-
Vertex and Verve announced they had entered an exclusive four-year research partnership to discover and nurture a gene editing therapy for yet-undisclosed liver disease.
-
Verve Therapeutics dosed its first patient with VERVE-101, a one-time treatment that aims to permanently lower low-density lipoprotein (LDL) cholesterol in patients and prevent heart disease.
-
When Sekar Kathiresan's brother unexpectedly died from a heart attack, he changed the course of his life to found a company with a novel medicine that may prevent them.
-
23andMe, EQRx Lead IPO Rush in 2021
12/21/2021
The year kicked off with a bang as multiple companies raced to a public listing. -
BioSpace Movers & Shakers, Dec. 3
12/3/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Money on the Move: June 16 – 22
6/23/2021
Life sciences advances continue to be an exciting opportunity for investors. Here's a glance at the companies attracting fresh funding the past week. -
Verve Therapeutics Announces Pricing of Initial Public Offering
6/17/2021
Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its initial public offering of 14,035,789 shares of its common stock at a price to the public of $19.00 per share
-
Biotech companies are dominating Nasdaq’s IPO scheduled this week. Here’s who is making their big public debut.
-
Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors
6/1/2021
Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that Michael F. MacLean, chief financial officer of Avidity Biosciences, has joined the company’s board of directors.
-
Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates
5/19/2021
Data Support Continued Development of Single-course Gene Editing Therapies for Treatment of Cardiovascular Disease, Led by VERVE-101